Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-44234

Buehler, P W; D'Agnillo, F; Schaer, D J (2010). Hemoglobin-based oxygen carriers: from mechanisms of toxicity and clearance to rational drug design. Trends in Molecular Medicine, 16(10):447-457.

[img] PDF - Registered users only


Hemoglobin-based oxygen carriers (HBOCs) have been developed to support blood oxygen transport capacity during hemorrhagic shock, hemolysis and ischemic insult. Existing product candidates have demonstrated considerable efficacy in experimental animal models and in clinical trial subjects; however, severe adverse safety signals that appeared in recent phase II and phase III clinical trials involving certain HBOCs have in part hindered further development and licensing. Emerging insights into hemoglobin (Hb) toxicity as well as physiologic Hb scavengers such as haptoglobin and CD163 that are capable of detoxifying extracellular Hb in vivo suggest that alternative product candidates could be designed. Together with novel animal models and biomarkers tailored to monitor the effects of extracellular Hb, a new generation of HBOCs can be envisioned.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic and Policlinic for Internal Medicine
DDC:610 Medicine & health
Deposited On:01 Feb 2011 16:20
Last Modified:27 Nov 2013 18:29
Publisher DOI:10.1016/j.molmed.2010.07.006
PubMed ID:20708968
Citations:Web of Science®. Times Cited: 21
Google Scholar™
Scopus®. Citation Count: 23

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page